For Geschäftsführer and CEOs at Swiss family-owned Mittelstand and precision-led firms entering the US market when a long-standing global pharma, medtech, or industrial OEM relationship consolidates US capacity, an FDA, FedRAMP, or US health-system pathway opens, or a second-generation principal returns from the United States with a new commercial thesis.
A Swiss specialty pharma, medtech, or precision-machinery firm has either landed an opportunistic US OEM or US health-system inquiry, or has been pulled into a US capacity build by a global pharma or industrial parent consolidating to US plants. Switzerland Global Enterprise trade-mission appearances at IMTS, MEDICA, RSNA, BIO International, HIMSS, or RSA generated US opportunistic interest. A second-generation principal who spent three to five years in the United States, often through a US business school, a US engineering rotation, or a US subsidiary leadership role, has returned to the family firm and named US scale as the next decade.
US policy shifts compound the trigger. The Inflation Reduction Act and Section 30D battery-localisation rules pulled European industrial supply toward US plants. The CHIPS and Science Act opened semiconductor, downstream-tooling, and precision-instrument capex cycles. FDA Drug Shortage Task Force priorities and Buy American Act contract preferences pulled US federal pharma and medtech procurement into US-content-first contracts. FedRAMP Rev 5 baselines, NIST SP 800-171 / 53, and CMMC 2.0 levels shape Swiss cyber and dual-use software entry into US federal accounts.
A third trigger is private capital. A Zurich, Geneva, or Munich family-office introduction opens a potential US acquisition or US joint-venture path. The firm is suddenly evaluated by US capital partners and US strategic counterparties on US commercial readiness rather than on the home-market track record alone.
The product is not the problem. The Swiss precision is not the problem. The US-facing frame around the product is, and the frame is fixable.
Annual revenue between ten million and one billion Swiss franc. Home-market product-market fit confirmed across at least one decade of European and global OEM, hospital, pharma, or industrial relationships. A US presence either already opened or imminently opening within the next twelve months. A Geschäftsführer or CEO who has named US scale as a strategic priority and is prepared to commit budget to a commercial rebuild rather than to additional translation work.
Out of scope. Firms still validating product-market fit in the home market. Firms whose US ambition is a single distributor relationship without direct US presence. Firms expecting US revenue to follow from English translation of home-market collateral. Firms unwilling to commit to a discovery conversation before scope is set. Firms whose primary need is legal, visa, regulatory, or tax structuring; those belong with specialist counsel.
Corridor reading sits in the Germany to USA market entry 2026 guide (the procurement logic carries directly into the Swiss context), the German medtech MDR to FDA bridge for medtech-specific reading, and the Germany to United States corridor page for adjacent sector framing.
One US category claim, one US installed-base or US health-system peer-set anchor, one US service-architecture statement, written so a US OEM, US health system, US pharma prime, or US federal procurement reader places the firm inside twenty seconds.
See the audience page →An English-language response stack written for the US procurement reader: cover letter posture, executive summary, US installed base, US service and parts, US-firm USD pricing, US compliance and regulatory mapping, and a US peer reference list.
Read the handbook →Geschäftsführer LinkedIn, US-readable biography, US-facing talks and panels, US podcast and trade-publication appearances. A second voice for the US conversation, in parallel with the Swiss voice that keeps running at home.
Browse the Knowledge hub →Six to ten weeks. One US category, one corridor. Positioning, US procurement messaging, RFQ response architecture, and the first US-readable materials stack rebuilt and shipped.
See the Sprint →Three to six months. Multi-channel US rebuild and run. Site, deck, RFQ stack, US service and parts architecture, principal register, and conversion cadence.
See the Build →Monthly retainer, twelve-month minimum. Ongoing US rebuild-and-run across multiple operating brands or pharma-medtech-industrial portfolios.
See the Partnership →Named case studies are added to Case studies as client opt-in is secured.
No legal services. No AG, GmbH, or US entity formation. No L-1, E-2, EB-5, or O-1 visa work. No US tax structuring, transfer pricing, FATCA analysis, or Swiss-US double-taxation treaty review. No US banking introductions. No regulatory licensing, FDA submission preparation, OSHA, EPA, or CE-mark work. No fiduciary services. No IP filing or contract drafting. No US recruiting or executive search. No M&A advisory. No FINMA-regulated activity.
These belong with Swiss counsel who specialise in US entry, with US counsel on the American side, and with regulatory consultants who handle US machine-safety, US medical-device, US pharma, US federal-cyber, and US product-liability pathways.
Geschäftsführer, CEOs, and US-entry coordinators at Swiss Mittelstand and family-firm operators with ten million to one billion Swiss franc in annual revenue, multi-decade operating history, and home-market product-market fit. Typical clusters: Basel pharma and life-sciences, Zurich and Bern medtech, Zentralschweiz precision machinery and food-processing equipment, Aargau and Schaffhausen industrial cluster, Zürich and Geneva industrial software and fintech.
Swiss materials carry an unusually quiet trust signal: SQS, SAS, SIA, ISO, multi-decade Swiss operating reputation, and CHF-denominated quotes positioned discreetly. The register works on a buyer who already knows what Swiss precision means. The US procurement reader does not start there. The US reader reads in category-first mode and asks four questions in sequence: which US category, which US installed base, which US service architecture, and which US firm pricing. The Swiss file answers the wrong question first.
Annual revenue between ten million and one billion Swiss franc, home-market product-market fit confirmed across at least one decade of European and global OEM, hospital, pharma, or industrial relationships, a US presence already opened or imminently opening, and explicit commitment to rebuilding the US-facing commercial layer rather than translating home-market materials.
A US sales hire dropped into the existing Swiss frame. A US subsidiary opened with the website unchanged. Switzerland Global Enterprise trade-mission appearances. A US distributor signed who relays specifications but cannot represent the firm in the US procurement conversation. The pattern is consistent across the Swiss corridor.
With an inquiry through the contact form and a discovery conversation. Three engagement shapes: Market Entry Sprint (six to ten weeks), Cross-Border Build (three to six months), or Group Partnership (monthly retainer, twelve-month minimum). Pricing is confirmed in discovery, not on the public site.
The DACH country-pair flagship. Sector spread, signal-break diagnosis, and three reference engagement profiles.
See the corridor →How a Swiss or German medtech firm bridges from CE-MDR to FDA 510(k), de novo, or PMA.
Read the handbook →The combined DACH corridor reading for groups operating across Germany, Austria, and Switzerland.
See the corridor →